SLRX NASDAQ
Salarius Pharmaceuticals, Inc.
1W: -0.5%
1M: -25.4%
3M: -82.9%
1Y: -97.4%
3Y: -99.5%
5Y: -100.0%
$0.84
Last traded 2025-12-31 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Revenue Segmentation
By Product / Service
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
$0
+56.0% ▲
Operating Income
-$6M
+55.5% ▲
Net Income
-$6M
+55.5% ▲
EPS (Diluted)
$-86.85
-152268.4% ▼
EBITDA
-$6M
-195867.4% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $5M | $0 | $0 | $0 | $0 |
| YoY Growth | +51.0% | -64.8% | -100.0% | +0.0% | +0.0% |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $5M | $0 | $0 | $0 | $0 |
| Gross Margin | 100.0% | — | — | — | — |
| R&D Expenses | $7M | $9M | $16M | $7M | $770K |
| SG&A Expenses | $6M | $6M | $7M | $6M | $5M |
| Operating Expenses | $13M | $13M | $32M | $13M | $6M |
| Operating Income | -$8M | -$13M | -$32M | -$13M | -$6M |
| Operating Margin | -148.8% | — | — | — | — |
| Interest Expense | $3K | $0 | $0 | $0 | $0 |
| Income Before Tax | -$7M | -$13M | -$32M | -$13M | -$6M |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$7M | -$13M | -$32M | -$13M | -$6M |
| Net Margin | -140.5% | — | — | — | — |
| EPS (Diluted) | $-1500.00 | $-930.00 | $-221.55 | $-0.06 | $-86.85 |
| EBITDA | -$8M | -$13M | -$23M | -$13M | -$6M |
| Shares Outstanding | 5219 | 13858 | 142342 | 218730 | 64468 |